News | October 30, 2022
Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Revenue from operations up 26% to Rs. 768 crores
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
Plans to double its manufacturing footprint to bolster the growth
UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
Subscribe To Our Newsletter & Stay Updated
